Peptonic Medical files patent application for an intimate wash based on VagiVital®

  • -

Peptonic Medical AB (publ) (’Peptonic’ or ’Company’) today announced that it has filed a patent application for and intimate wash based on the Company’s vaginal gel VagiVital® and a specifically selected oil.

The market as well as the number of applications of products for intimate health are growing. And fastest of these the intimate washes, that can generally be divided into soaps and oils. The challenge for an intimate wash is to clean without causing undesired effects in this delicate area of the body. Peptonic has identified a method to meet this challenge by developing an intimate wash based on its gentle and water-based vaginal gel VagiVital® in combination with an oil. This combination will give the product a unique position on the market, which is why the patent application has been filed.

– To be able to stabilise a water-based gel like VagiVital® including an oil is unique and gives us the opportunity to introduce a new type of gentle and soothing gel wash on the market, says Johan Inborr, CEO of Peptonic Medical. This is a welcome addition to the VagiVital® brand. 

VagiVital® is a CE marked product for treating symptoms associated with vaginal atrophy.

The patent application has been filed with the The Swedish Intellectual Property Office.

For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
E-mail:  johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14th May, 2020.


About  VagiVital®

VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (seewww.vagivital.com).  

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.se, ticker: PMED) in Stockholm, Sweden. 

For more information: www.peptonicmedical.com